Improving cancer survival rates are real success stories that sometime get lost in the noise over our healthcare system. However, "Targeted drugs are driving that survival in a major way.
Some cancer drugs like Sutent have proven effective for both stomach and kidney cancer and are likely to give benefits in both the cases as per the reports from the late phase clinical trials. Sutent (Pfizer Oncology product) has become one of the more expensive cancer drugs on the market at around $50,000. But even at that price, it's become key to a treatment approach known as daisy-chaining, in which patients use one drug until it stops working, then move on to another. Some patients have survived as long as seven years this way.